Learn peptides step by step

Pemvidutide, MASH, and the Liver-Waist Signal: Why Weight Loss Alone Misses the Point

Pemvidutide is interesting because it does not just ask whether body weight falls. It asks whether liver fat, waist size, appetite, and recovery move together in a clean direction.

10m

Retatrutide Compounding Quality Control: Why the Debate Matters More Than Hype

Retatrutide may dominate the weight-loss discussion, but the market debate is really about quality control, documentation, and whether a plan can survive real life.

Retatrutide in 2026: Why the Strongest Weight-Loss Signal Still Needs Body-Composition Tracking

Retatrutide is still the loudest metabolic signal in the room. The people who get the best result are the ones who track body composition, not just pounds lost.

Amycretin Beginner's Guide: Novo's GLP-1 + Amylin Dual Agonist

Amycretin puts GLP-1 and amylin in one molecule — with both a pill and a weekly shot in development. Here's the beginner map before Phase 3 ladders finalize.

Amycretin Dosing Guide: Oral Daily and Weekly Subcutaneous Protocols

Amycretin is Novo's dual GLP-1 + amylin molecule with both oral and injectable programs. Here's the early dosing map and why Phase 3 is the next SEO wave.

CT-388 Dosing Guide: Weekly Dual GLP-1/GIP Up to 24 mg

CT-388 is Roche's weekly tirzepatide-class dual agonist with Phase 2 doses up to 24 mg. Here's the dosing vocabulary and the weight-loss signal searchers want.

Eloralintide Beginner's Guide: What LY3841136 Is and Why Amylin Matters

Eloralintide is Lilly's once-weekly selective amylin receptor agonist. If you follow GLP-1s, CagriSema, or retatrutide, this is the next pathway to understand — satiety biology, trial doses, and what the early data actually show.

Eloralintide Dosing Guide: Phase 2 Doses, Titration, and Weekly Protocol

Searching for eloralintide dosage? Here is the clean map of Phase 2 once-weekly doses, titration arms, and weight-loss results — framed as clinical education, not a DIY protocol.

Eloralintide vs Cagrilintide: Amylin Agonists Compared

Both hit amylin biology. One is Lilly's Phase 3 monotherapy / combo candidate. The other is the amylin half of CagriSema. Here's a clear comparison for people following the next wave of obesity peptides.

SafetyIntermediate

MariTide Beginner's Guide: What Maridebart Cafraglutide Is

MariTide is Amgen's once-monthly obesity candidate. This beginner guide covers the mechanism framing, Phase 2 headlines, and what serious trackers should log.

MariTide Dosing Guide: Once-Monthly 140–420 mg Phase 2 Map

MariTide is the once-monthly obesity candidate people keep comparing to weekly GLP-1s. Here's the Phase 2 dosing map — 140 / 280 / 420 mg and the escalation arms that mattered for tolerability.

MariTide vs Weekly GLP-1s: Monthly Conjugate vs Weekly Agonists

Weekly vs monthly is the real MariTide comparison. Here's how Amgen's conjugate stacks up conceptually against weekly dual/triple agonists — without fake head-to-heads.

Survodutide Dosing Guide: Phase 2–3 Weekly Doses for Obesity

Survodutide is Boehringer's glucagon/GLP-1 dual agonist. Here's the dosing map from dose-finding through Phase 3 — weekly mg ranges, escalation logic, and what the weight-loss data showed.

Retatrutide Weight-Loss Data: What the New Numbers Mean for Body Composition

Retatrutide is forcing a better conversation about fat loss. The scale matters, but body composition, protein, and strength tell you whether the result will hold.

Retatrutide and Body Composition: Why the Real Story Is Adherence, Not Just Scale Weight

The best metabolic tools do more than move the scale. They change how easy it is to follow the plan on day 3, day 30, and day 300.

Retatrutide and Food Noise: Why Appetite Control Changes Adherence

The scale is only part of the story. Retatrutide's biggest advantage may be how it quiets food noise and makes adherence easier to sustain.

Retatrutide Is Approaching Surgery-Level Weight Loss: What the New Data Actually Means

Retatrutide's weight-loss signal is now strong enough that people are comparing it with surgery. That comparison is useful, but only if you understand what the numbers do and do not mean.

Retatrutide and Chronic Kidney Disease: What the 2026 Meta-Analysis Adds

Retatrutide is no longer just a weight-loss story. The latest kidney-aware review sharpens the question: which metabolic patients need tighter monitoring, slower escalation, and better data?

Retatrutide Trials in 2026: Back Pain, Liver, Heart, and Muscle Signals to Watch

Retatrutide is no longer just a weight-loss headline. Current 2026 trial records show researchers testing broader questions: pain, liver disease, cardiorenal risk, dose escalation, and lean-mass preservation.

GLP-1 Food Noise: Why It Comes Back After Stopping and What Actually Helps

Food noise — that constant mental chatter about food — often comes back after stopping GLP-1 peptides. Here's the science of why, and what actually helps: maintenance strategies, stacking options, and realistic expectations.

10m

Retatrutide Phase 3 Results: 28.7% Body Weight Reduction Sets a New Standard

Phase 3 trial data is in: retatrutide delivers 28.7% average body weight reduction, outpacing every approved GLP-1 therapy. The numbers tell a clear story about where metabolic medicine is heading.

11m

Why Retatrutide is Winning: Clinical Data Shows 28% Superior Fat Loss Over GLP-1

A 2026 meta-analysis comparing retatrutide to GLP-1 (Ozempic/Wegovy) and tirzepatide shows retatrutide delivers 28% superior fat loss. Here's the science behind why the triple-agonist approach is reshaping weight loss and body recomposition.

Retatrutide Phase 3 Results: What the Clinical Data Tells Us

New Phase 3 data shows retatrutide delivering superior metabolic benefits. Here's what researchers found and why it matters.

10m